> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Suzhou Pharmaceutical CGMP Violations
- URL: https://www.fdaweb.com/suzhou-pharmaceutical-cgmp-violations/
- Published: 2017-01-17T12:00:00.000Z
- Updated: 2026-09-14T22:00:31.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5137742

A 6/6-6/8/16 FDA inspection at Suzhou Pharmaceutical Technology, Suzhou, China, found significant deviations from current good manufacturing practice regulations for active pharmaceutical ingredients (APIs), according to a 1/6 [Warning Letter](http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2017/ucm536866.htm?ref=fdaweb.com). Specific deviations cited in the letter include: 

- failing to transfer all quality or regulatory information received from the API manufacturer to customers;
- failing to have a quality unit responsible for reviewing and approving all appropriate quality-related documents, including certificates of analysis; and
- failing to have facilities suitable for storing all materials under appropriate conditions.

The letter notes that the firm shipped APIs in 5/2015 to the U.S. that were obtained from a manufacturer that was under an FDA import alert. The agency says it strongly recommends that the company engage a consultant qualified to evaluate its operations and assist it in meeting CGMP requirements.

Suzhou was told to submit: **(1)** written procedures for the transfer of quality and regulatory information to its customers, including specific details of the information it will transfer; **(2)** a plan to establish, document, and implement an effective system for managing quality, including written procedures for CGMP-related activities and the personnel responsible for oversight; and **(3)** corrective actions for establishing and maintaining adequate storage conditions.

FDA placed the company on an import alert 10/17/16\. It told the firm to respond with steps taken since the inspection to correct the deviations and prevent their recurrence, along with a timetable for completion.